[go: up one dir, main page]

WO2002055548A8 - Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use - Google Patents

Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Info

Publication number
WO2002055548A8
WO2002055548A8 PCT/EP2002/000219 EP0200219W WO02055548A8 WO 2002055548 A8 WO2002055548 A8 WO 2002055548A8 EP 0200219 W EP0200219 W EP 0200219W WO 02055548 A8 WO02055548 A8 WO 02055548A8
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnostic
envelope proteins
present
therapeutic use
Prior art date
Application number
PCT/EP2002/000219
Other languages
French (fr)
Other versions
WO2002055548A2 (en
WO2002055548A3 (en
Inventor
Geert Maertens
Fons Bosman
Marie-Ange Buyse
Original Assignee
Innogenetics Nv
Geert Maertens
Fons Bosman
Marie-Ange Buyse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020027011431A priority Critical patent/KR20020089371A/en
Priority to EP02704649A priority patent/EP1463753A2/en
Priority to CA002400643A priority patent/CA2400643A1/en
Priority to AU2002238502A priority patent/AU2002238502B2/en
Priority to HU0302416A priority patent/HUP0302416A2/en
Priority to MXPA02008886A priority patent/MXPA02008886A/en
Priority to JP2002556616A priority patent/JP2004525885A/en
Priority to BR0203518-9A priority patent/BR0203518A/en
Application filed by Innogenetics Nv, Geert Maertens, Fons Bosman, Marie-Ange Buyse filed Critical Innogenetics Nv
Priority to NZ521299A priority patent/NZ521299A/en
Priority to PL02363175A priority patent/PL363175A1/en
Priority to IL15103302A priority patent/IL151033A0/en
Publication of WO2002055548A2 publication Critical patent/WO2002055548A2/en
Priority to NO20024325A priority patent/NO20024325L/en
Publication of WO2002055548A8 publication Critical patent/WO2002055548A8/en
Publication of WO2002055548A3 publication Critical patent/WO2002055548A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic ad therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome if HCV treatment.
PCT/EP2002/000219 2001-01-10 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use WO2002055548A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2002556616A JP2004525885A (en) 2001-01-10 2002-01-11 Purified hepatitis C virus envelope protein for diagnostic and therapeutic use
CA002400643A CA2400643A1 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU2002238502A AU2002238502B2 (en) 2001-01-11 2002-01-11 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
HU0302416A HUP0302416A2 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
MXPA02008886A MXPA02008886A (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use.
BR0203518-9A BR0203518A (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
NZ521299A NZ521299A (en) 2001-01-11 2002-01-11 Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
KR1020027011431A KR20020089371A (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EP02704649A EP1463753A2 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
PL02363175A PL363175A1 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
IL15103302A IL151033A0 (en) 2001-01-11 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
NO20024325A NO20024325L (en) 2001-01-11 2002-09-10 Purified hepatitis C virus envelope proteins for diagnosis and therapeutic use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26066901P 2001-01-11 2001-01-11
US60/260,669 2001-01-11
US31576801P 2001-08-30 2001-08-30
US60/315,768 2001-08-30

Publications (3)

Publication Number Publication Date
WO2002055548A2 WO2002055548A2 (en) 2002-07-18
WO2002055548A8 true WO2002055548A8 (en) 2002-10-31
WO2002055548A3 WO2002055548A3 (en) 2004-08-05

Family

ID=26948130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000219 WO2002055548A2 (en) 2001-01-10 2002-01-11 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Country Status (16)

Country Link
EP (1) EP1463753A2 (en)
KR (1) KR20020089371A (en)
CN (1) CN1547588A (en)
AR (1) AR032240A1 (en)
AU (1) AU2002238502B2 (en)
BR (1) BR0203518A (en)
CA (1) CA2400643A1 (en)
CZ (1) CZ20032164A3 (en)
HU (1) HUP0302416A2 (en)
IL (1) IL151033A0 (en)
MX (1) MXPA02008886A (en)
NO (1) NO20024325L (en)
PL (1) PL363175A1 (en)
RU (1) RU2313363C2 (en)
TR (1) TR200202169T1 (en)
WO (1) WO2002055548A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086101A2 (en) 2001-04-24 2002-10-31 Innogenetics N.V. Core-glycosylated hcv envelope proteins
AU2003283365A1 (en) * 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
EP2267004A3 (en) * 2003-09-22 2011-04-27 Green Peptide Co., Ltd. Peptide derived from hepatitis C virus
CN100365124C (en) * 2005-10-27 2008-01-30 云南大学 Determination and application of hepatitis C virus specific cDNA sequence
CN115980352A (en) * 2022-12-30 2023-04-18 宁波博肽生物技术有限公司 A kind of HCV antigen coating pretreatment agent, antigen coating method and detection kit

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Also Published As

Publication number Publication date
RU2313363C2 (en) 2007-12-27
MXPA02008886A (en) 2003-04-25
RU2002121632A (en) 2004-03-20
IL151033A0 (en) 2003-04-10
CZ20032164A3 (en) 2003-10-15
PL363175A1 (en) 2004-11-15
EP1463753A2 (en) 2004-10-06
CN1547588A (en) 2004-11-17
NO20024325D0 (en) 2002-09-10
HUP0302416A2 (en) 2003-10-28
AU2002238502B2 (en) 2007-09-06
WO2002055548A2 (en) 2002-07-18
KR20020089371A (en) 2002-11-29
WO2002055548A3 (en) 2004-08-05
AU2002238502A1 (en) 2002-07-24
BR0203518A (en) 2002-12-17
AU2002238502B9 (en) 2002-07-24
CA2400643A1 (en) 2002-07-18
TR200202169T1 (en) 2004-06-21
AR032240A1 (en) 2003-10-29
NO20024325L (en) 2002-11-11

Similar Documents

Publication Publication Date Title
WO1996004385A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2003051912A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
Usami et al. A 28-kDa protein with disintegrin-like structure (jararhagin-C) purified from Bothrops jararaca venom inhibits collagen-and ADP-induced platelet aggregation
Randolph et al. Amino acid sequence of fibrolase, a direct‐acting fibrinolytic enzyme from agkistrodon contortrix contortrix venom
WO2002086100A3 (en) Expression of core-glycosylated hcv envelope proteins in yeast
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
DE69922958D1 (en) HCV HULL PROTEINS PARTICLES: USE FOR THERAPEUTIC VACCINATION
JP2001514858A5 (en)
ATE478944T1 (en) CYTOKINE LIGAND FOR THE TREATMENT OF ASTHMA AND AIRWAY HYPERREACTIVITY
EP1197220A3 (en) Therapeutic methods and compositions based on delta proteins and nucleic acids
WO1995001442A3 (en) Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines
JP2004536077A5 (en)
EP0837131A3 (en) Staphylococcus fibronectin binding protein compounds
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
WO2004048402B1 (en) A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
WO2006131749A3 (en) Scaffold
MXPA05005202A (en) Vaccine.
WO2002055548A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2005052159A8 (en) Latent phase viral interleukin-10-(vii-10) and uses thereof
WO2004087062A3 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
EP0834568A3 (en) Novel saliva binding protein
WO2004014936A3 (en) Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof
Holtet et al. Receptor‐binding domain of human α2‐macroglobulin Expression, folding and biochemical characterization of a high‐affinity recombinant derivative
EP0839910A3 (en) Spo-rel, a Staphylococcus relA/spot homologue
JPH1080281A (en) New protein and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 151033

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00764/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002238502

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2400643

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027011431

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2002 556616

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002/07272

Country of ref document: ZA

Ref document number: 200207272

Country of ref document: ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008886

Country of ref document: MX

Ref document number: 521299

Country of ref document: NZ

Ref document number: 2002/02169

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2002704649

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 29/2002 UNDER (30) REPLACE "60/260699" BY "60/260669"

ENP Entry into the national phase

Ref document number: 2002 2002121632

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 028006097

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027011431

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2003-2164

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: PV2003-2164

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002704649

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521299

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521299

Country of ref document: NZ